PeptideStack
5.2kquestions
20kanswers
220users

Does hydrolysis dominate for orforglipron held at 4 °C?

Asked 14 Apr 2026Modified 2 months agoViewed 2.2k times
13

Details up front: hydrolysis · orforglipron · 4 °C.

I can predict the outcome but I cannot explain it, which means I will get the next case wrong.

I would like to know how confident the field actually is about this.

So what is the mechanism, and how well established is it?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
shareeditfollowflag
HP
askedhana_petrikova10k1414 Apr 2026

2 Answers

Accepted answer first, then by votes
23

Accepted answer

At 4 °C the question is which route is fastest, not whether hydrolysis happens — and the routes do not share an activation energy, so their ranking changes with temperature. 4 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. That multiplier is an average over every route at once, which is exactly why it cannot tell you which one wins. Backbone amide bonds cleave, so every product is shorter than the parent and the mass ladder they leave behind is the evidence that it happened. So the way to answer it for your vial is to pick the method that sees hydrolysis specifically and run it against a control held cold, rather than to infer a mechanism from a purity number that averages all of them.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Stated carefully, hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
DL
answered · acceptedDr_Otto_Lindqvist72k5811 Jun 2026
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
18

Start with the sequence, because which pathways are available depends on which residues are present.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
HN
answeredhalvard_ness69k4731 May 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.